# EDGAR Filing Document

**Accession Number:** 0001759425
**File Stem:** 0001759425-26-000015
**Filing Date:** 2026-2
**Character Count:** 30822
**Document Hash:** 0c20d0844a98c7404d89968d152d6106
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001759425-26-000015.hdr.sgml**: 20260225

**ACCESSION NUMBER**: 0001759425-26-000015

**CONFORMED SUBMISSION TYPE**: S-8

**PUBLIC DOCUMENT COUNT**: 15

**FILED AS OF DATE**: 20260225

**DATE AS OF CHANGE**: 20260225

**EFFECTIVENESS DATE**: 20260225

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Mirum Pharmaceuticals, Inc.
- **CENTRAL INDEX KEY:** 0001759425
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 831281555
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** S-8
- **SEC ACT:** 1933 Act
- **SEC FILE NUMBER:** 333-293748
- **FILM NUMBER:** 26679338

**BUSINESS ADDRESS:**
- **STREET 1:** 989 EAST HILLSDALE BOULEVARD, SUITE 300
- **CITY:** FOSTER CITY
- **STATE:** CA
- **ZIP:** 94404
- **BUSINESS PHONE:** 650-667-4085

**MAIL ADDRESS:**
- **STREET 1:** 989 EAST HILLSDALE BOULEVARD, SUITE 300
- **CITY:** FOSTER CITY
- **STATE:** CA
- **ZIP:** 94404

**As filed with the Securities and Exchange Commission on February 25, 2026**

**Registration No. 333-**

**______________________________________________________________________________________________________________**

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**______________________________________________________________________________________________________________**

**FORM S-8** 

**REGISTRATION STATEMENT**

***UNDER***

***THE SECURITIES ACT OF 1933***

**______________________________________________________________________________________________________________**

**Mirum Pharmaceuticals, Inc.**

**(Exact name of registrant as specified in its charter)**

**______________________________________________________________________________________________________________**

---

| | |
|:---|:---|
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**Delaware** | **83-1281555** |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**(State or other jurisdiction of incorporation or organization)** | **(I.R.S. Employer Identification No.)** |
| &nbsp;&nbsp;&nbsp;&nbsp;**989 East Hillsdale Boulevard, Suite 300**<br>**Foster City, California** | <br>**94404** |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**(Address of Principal Executive Offices)** | &nbsp;&nbsp;**(Zip Code)** |

---

**______________________________________________________________________________________________________________**

**2019 Equity Incentive Plan** 

**2019 Employee Stock Purchase Plan**

**(Full titles of the plans)**

**______________________________________________________________________________________________________________**

**Christopher Peetz** 

**Chief Executive Officer**

**Mirum Pharmaceuticals, Inc.** 

**989 East Hillsdale Boulevard, Suite 300**

 **Foster City, California 94404 (650) 667-4085**

**(Name, address, including zip code, and telephone number, including area code, of agent for service)**

**______________________________________________________________________________________________________________**

***Copies to:***

**Jason L. Kent** 

**Julia R. Boesch**

**Cooley LLP**

**55 Hudson Yards**

**New York, New York**

 **(212) 479-6000**

**Douglas Sheehy**

**Chief Legal Officer & Secretary**

**Mirum Pharmaceuticals, Inc.**

**989 East Hillsdale Boulevard, Suite 300**

**Foster City, California 94404**

**(650) 667-4085**

**______________________________________________________________________________________________________________**

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company," and "emerging growth company" in Rule 12b-2 of the Exchange Act.

---

| | | | |
|:---|:---|:---|:---|
| Large accelerated filer | &nbsp;&nbsp;&nbsp;☒ | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Accelerated filer | ☐ |
| Non-accelerated filer | &nbsp;&nbsp;&nbsp;☐ | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Smaller reporting company | ☐ |
| | | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Emerging growth company | ☐ |

---

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐

------

**EXPLANATORY NOTE**

This Registration Statement on Form S-8 (this "Registration Statement") is being filed by Mirum Pharmaceuticals, Inc. (the "Registrant") for the purpose of registering (i) 2,594,819 additional shares of the Registrant's common stock, par value $0.0001 ("Common Stock"), under the Registrant's 2019 Equity Incentive Plan (the "2019 Plan"), pursuant to the provisions of the 2019 Plan providing for an automatic increase in the number of shares of Common Stock reserved and available for issuance under the 2019 Plan and (ii) 518,963 additional shares of the Registrant's Common Stock under the Registrant's 2019 Employee Stock Purchase Plan (the "2019 ESPP"), pursuant to the provisions of the 2019 ESPP providing for an automatic increase in the number of shares of Common Stock reserved and available for issuance under the 2019 ESPP.

These additional shares of Common Stock are securities of the same class as other securities for which Registration Statements of the Registrant on Form S-8 relating to the same employee benefit plans are effective.

**PART II**

**INFORMATION REQUIRED IN THE REGISTRATION STATEMENT**

**Item 3. Incorporation of Documents by Reference.**

The Registrant previously registered shares of Common Stock for issuance under the 2019 Plan and the 2019 ESPP pursuant to (i) a Registration Statement on <u>[Form S-8](https://www.sec.gov/Archives/edgar/data/0001759425/000119312519232544/d797282ds8.htm)</u> (File No. 333-233502) filed with the Securities and Exchange Commission (the "Commission") on August 28, 2019, (ii) a Registration Statement on <u>[Fo](https://www.sec.gov/Archives/edgar/data/0001759425/000156459020023010/mirm-s8.htm)[rm S-8](https://www.sec.gov/Archives/edgar/data/0001759425/000156459020023010/mirm-s8.htm)</u> (File No. 333-238086) filed with the Commission on May 7, 2020, (iii) a Registration Statement on <u>[Form S-8](https://www.sec.gov/Archives/edgar/data/0001759425/000156459021011788/mirm-s8.htm)</u> (File No. 333-254043) filed with the Commission on March 9, 2021, (iv) a Registration Statement on <u>[Form S-8](https://www.sec.gov/Archives/edgar/data/0001759425/000119312522070703/d318573ds8.htm)</u> (File No. 333-263397) filed with the Commission on March 9, 2022, (v) a Registration Statement on <u>[Form S-8](https://www.sec.gov/Archives/edgar/data/0001759425/000119312523066124/d475530ds8.htm)</u> (File No. 333-270399) filed with the Commission on March 9, 2023, (vi) a Registration Statement on <u>[Form S-8](https://www.sec.gov/Archives/edgar/data/0001759425/000119312524069301/d794200ds8.htm)</u> (File No. 333-278011) filed with the Commission on March 15, 2024 and (vii) a Registration Statement on <u>[F](https://www.sec.gov/Archives/edgar/data/0001759425/000175942525000016/mirm-sx820250226.htm)[orm S-8](https://www.sec.gov/Archives/edgar/data/0001759425/000175942525000016/mirm-sx820250226.htm)</u> (File No. 333-285272) filed with the Commission on February 26, 2025 (collectively, the "Prior Registration Statements"). In accordance with General Instruction E to Form S-8, the contents of the Prior Registration Statements are hereby incorporated by reference.

The Registrant hereby incorporates by reference into this Registration Statement the following documents previously filed by the Registrant with the Commission:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)The Registrant's Annual Report on <u>[Form 10-K](https://www.sec.gov/ix?doc=/Archives/edgar/data/0001759425/000175942526000013/mirm-20251231.htm)</u> for the year ended December 31, 2025, filed with the Commission on February 25, 2026 (the "2025 Annual Report");

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)The description of the Registrant's Common Stock contained in the Registrant's Registration Statement on <u>[Form 8-A](https://www.sec.gov/Archives/edgar/data/1759425/000119312519194022/d711354d8a12b.htm)</u> (File No. 001-38981) filed with the Commission on July 15, 2019 under Section 12(b) of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), including any amendment or report filed for the purpose of updating such description, including <u>[Exhibit 4.3](https://www.sec.gov/Archives/edgar/data/1759425/000095017024032289/mirm-ex4_3.htm)</u> to the Registrant's Annual Report on Form 10-K for the year ended December 31, 2023; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c)The Registrant's Current Report on Form 8-K (other than information furnished rather than filed) filed with the Commission on <u>[January 26, 2026](https://www.sec.gov/ix?doc=/Archives/edgar/data/0001759425/000119312526022582/d35336d8k.htm)</u>.

All documents filed by the Registrant with the Commission pursuant to Section 13(a), 13(c), 14 or 15(d) of the Exchange Act after the date of this Registration Statement and prior to the filing of a post-effective amendment which indicates that all securities offered hereby have been sold or which deregisters all securities then remaining unsold, shall be deemed to be incorporated by reference into this Registration Statement and to be a part hereof from the date of filing of such documents; provided, however, that documents or portions thereof that are furnished and not filed in accordance with the rules of the Commission shall not be deemed incorporated by reference into this Registration Statement unless specifically stated to the contrary. Any statement contained in a document incorporated or deemed to be incorporated by reference herein shall be deemed to be modified or superseded for purposes of this Registration Statement to the extent that a statement herein or in any other subsequently filed document that also is or is deemed to be incorporated by reference herein modifies or supersedes such statement. Any such statement so modified or superseded shall not constitute a part of this Registration Statement, except as so modified or superseded.

------

**Item 8. Exhibits.**

The exhibits to this Registration Statement are listed below:

---

| | |
|:---|:---|
| **Exhibit**<br> **<u>Number</u>** | <br>**<u>&nbsp;&nbsp;&nbsp;&nbsp;Description&nbsp;&nbsp;&nbsp;&nbsp;</u>** |
| 4.1 | <u>[Amended and Restated Certificate of Incorporation of the Registrant (incorporated by reference to Exhibit 3.1 to the Registrant's Current Report on Form 8-K, filed with the Commission on July 25, 2019).](https://www.sec.gov/Archives/edgar/data/1759425/000119312519202499/d780544dex31.htm)</u> |
| 4.2 | <u>[Amended and Restated Bylaws of the Registrant (incorporated by reference to Exhibit 3.2 to the Registrant's Current Report on Form 8-K, filed with the Commission on July 25, 2019).](https://www.sec.gov/Archives/edgar/data/1759425/000119312519202499/d780544dex32.htm)</u> |
| 4.3 | <u>[Form of Common Stock Certificate of the Registrant (incorporated by reference to Exhibit 4.1 to the Registrant's Registration Statement on Form S-1 (File No. 333-232251), filed with the Commission on July 8, 2019).](https://www.sec.gov/Archives/edgar/data/1759425/000119312519189959/d730455dex41.htm)</u> |
| 5.1 | <u>[Opinion of Cooley LLP.](mirm-sx8xexx5120260225.htm)</u> |
| 23.1 | <u>[Consent of Independent Registered Public Accounting Firm.](mirm-sx8xexx23120260225.htm)</u> |
| 23.2 | <u>[Consent of Cooley LLP (included in Exhibit 5.1).](mirm-sx8xexx5120260225.htm)</u> |
| 24.1 | <u>[Power of Attorney (included on the signature page).](#i49a14f53dbd6411bb9fc2962b31d30e5_13)</u> |
| 99.1 | <u>[Mirum Pharmaceuticals, Inc.](https://www.sec.gov/Archives/edgar/data/1759425/000119312519189959/d730455dex103.htm)[2019](https://www.sec.gov/Archives/edgar/data/1759425/000119312519189959/d730455dex103.htm)[Equity Incentive](https://www.sec.gov/Archives/edgar/data/1759425/000119312519189959/d730455dex103.htm)[Plan](https://www.sec.gov/Archives/edgar/data/1759425/000119312519189959/d730455dex103.htm)[(incorporated by reference to Exhibit 10.3 to the Registrant](https://www.sec.gov/Archives/edgar/data/1759425/000119312519189959/d730455dex103.htm)['s Registration S](https://www.sec.gov/Archives/edgar/data/1759425/000119312519189959/d730455dex103.htm)[tatement on Form S-1, as amended (](https://www.sec.gov/Archives/edgar/data/1759425/000119312519189959/d730455dex103.htm)[File No. 333-232251),](https://www.sec.gov/Archives/edgar/data/1759425/000119312519189959/d730455dex103.htm)[filed](https://www.sec.gov/Archives/edgar/data/1759425/000119312519189959/d730455dex103.htm)[with the](https://www.sec.gov/Archives/edgar/data/1759425/000119312519189959/d730455dex103.htm)[Commission on](https://www.sec.gov/Archives/edgar/data/1759425/000119312519189959/d730455dex103.htm)[July](https://www.sec.gov/Archives/edgar/data/1759425/000119312519189959/d730455dex103.htm)[8](https://www.sec.gov/Archives/edgar/data/1759425/000119312519189959/d730455dex103.htm)[, 20](https://www.sec.gov/Archives/edgar/data/1759425/000119312519189959/d730455dex103.htm)[19](https://www.sec.gov/Archives/edgar/data/1759425/000119312519189959/d730455dex103.htm)[.](https://www.sec.gov/Archives/edgar/data/1759425/000119312519189959/d730455dex103.htm)</u> |
| 99.2 | <u>[M](https://www.sec.gov/Archives/edgar/data/1759425/000119312519189959/d730455dex106.htm)[irum Pharmaceuticals, Inc. 2019 Employ](https://www.sec.gov/Archives/edgar/data/1759425/000119312519189959/d730455dex106.htm)[ee Stock Purchase Plan (incorporated by reference to Exhibit 10.6 to the Registrant's Registration Statement on Form S-1, as amended (File No](https://www.sec.gov/Archives/edgar/data/1759425/000119312519189959/d730455dex106.htm)[. 333-232251),](https://www.sec.gov/Archives/edgar/data/1759425/000119312519189959/d730455dex106.htm)[filed with the Commission on July 8, 2019).](https://www.sec.gov/Archives/edgar/data/1759425/000119312519189959/d730455dex106.htm)</u> |
| 107 | <u>[Filing Fee Table.](exfilingfees.htm)</u> |

---

------

**SIGNATURES**

Pursuant to the requirements of the Securities Act of 1933, as amended, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Foster City, State of California, on February 25, 2026.

---

| |
|:---|
| **MIRUM PHARMACEUTICALS, INC.** |
| By:&nbsp;&nbsp;&nbsp;&nbsp;<u>/s/ Christopher Peetz&nbsp;&nbsp;&nbsp;&nbsp;</u> |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Christopher Peetz |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Chief Executive Officer |

---

------

**POWER OF ATTORNEY**

KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints Christopher Peetz, Eric Bjerkholt and Douglas Sheehy, and each one of them, as his or her true and lawful attorneys-in-fact and agents, with full power of substitution and resubstitution, for him or her and in their name, place and stead, in any and all capacities, to sign any and all amendments (including post-effective amendments) to this registration statement, and to file the same, with all exhibits thereto and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite and necessary to be done in connection therewith, as fully to all intents and purposes as he might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents or any of them, or his substitute or substitutes, may lawfully do or cause to be done by virtue hereof.

Pursuant to the requirements of the Securities Act of 1933, as amended, this Registration Statement has been signed by the following persons in the capacities and on the dates indicated.

---

| | | |
|:---|:---|:---|
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**<u>Signature</u>** | **<u>Title</u>** | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**<u>Date</u>** |
| /s/ Christopher Peetz | Chief Executive Officer and Director <br>(Principal Executive Officer) | February 25, 2026 |
| Christopher Peetz | Chief Executive Officer and Director <br>(Principal Executive Officer) |  |
| /s/ Eric Bjerkholt | Chief Financial Officer<br>(Principal Financial Officer) | February 25, 2026 |
| Eric Bjerkholt | Chief Financial Officer<br>(Principal Financial Officer) |  |
| /s/ Jody Howe | Senior Vice President, Global Controller<br>(Principal Accounting Officer) | February 25, 2026 |
| Jody Howe | Senior Vice President, Global Controller<br>(Principal Accounting Officer) |  |
| /s/ Laura Brege | Director | February 25, 2026 |
| Laura Brege |  |  |
| /s/ Lon Cardon, Ph.D. | Director | February 25, 2026 |
| Lon Cardon, Ph.D. |  |  |
| /s/ William C. Fairey | Director | February 25, 2026 |
| William C. Fairey |  |  |
| /s/ Laurent Fischer, M.D. | Director | February 25, 2026 |
| Laurent Fischer, M.D. |  |  |
| /s/ Michael Grey | Director | February 25, 2026 |
| Michael Grey |  |  |
| /s/ Patrick Heron | Director | February 25, 2026 |
| Patrick Heron |  |  |
| /s/ Saira Ramasastry, M.S., M.Phil. | Director | February 25, 2026 |
| Saira Ramasastry, M.S., M.Phil. |  |  |
| /s/ Timothy Walbert | Director | February 25, 2026 |
| Timothy Walbert |  |  |

---

## Ex-Filing

?xml version='1.0' encoding='ASCII'? EX-FILING FEES

---

| |
|:---|
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; **Calculation of Filing Fee Tables**  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; **S-8**  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; **Mirum Pharmaceuticals, Inc.**  |

---

---

| | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|
| | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; **Security Type**  | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; **Security Class Title**  | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; **Fee Calculation Rule**  | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; **Amount Registered**  | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; **Proposed Maximum Offering Price Per Unit**  | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; **Maximum Aggregate Offering Price**  | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; **Fee Rate**  | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; **Amount of Registration Fee**  |
| 1 | Equity | 2019 Equity Incentive Plan, Common Stock, $0.0001 per share | Other | 2594819 | $104.42 | $270950999.98 | 0.0001381 | $37418.33 |
| 2 | Equity | 2019 Employee Stock Incentive Plan Common Stock, $0.0001 per share | Other | 518963 | $88.757 | $46061598.99 | 0.0001381 | $6361.11 |
| Total Offering Amounts: | Total Offering Amounts: | Total Offering Amounts: | Total Offering Amounts: | Total Offering Amounts: |  | $317012598.97  |  | $43779.44  |
| Total Fee Offsets:  | Total Fee Offsets:  | Total Fee Offsets:  | Total Fee Offsets:  | Total Fee Offsets:  |  |  |  | $0.00  |
| Net Fee Due:  | Net Fee Due:  | Net Fee Due:  | Net Fee Due:  | Net Fee Due:  |  |  |  | $43779.44  |

---

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; **Offering Note** <br>

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <sup>1</sup> Pursuant to Rule 416(a) under the Securities Act of 1933, as amended (the Securities Act), this Registration Statement on Form S-8 (this Registration Statement) shall also cover any additional shares of common stock (Common Stock) of Mirum Pharmaceuticals, Inc. (the Registrant) that become issuable under the Registrants 2019 Equity Incentive Plan (the 2019 Plan) by reason of any stock dividend, stock split, recapitalization or other similar transaction. Estimated solely for the purpose of calculating the amount of the registration fee pursuant to Rules 457(c) and 457(h) of the Securities Act. The proposed maximum aggregate offering price per unit and proposed maximum aggregate offering price are calculated using the average of the high and low prices of the Common Stock as reported on the Nasdaq Global Market on February 20, 2026, which date is within five business days prior to the filing of this Registration Statement. The number of shares being registered represents shares of Common Stock that were automatically added to the shares available for issuance under the 2019 Plan on January 1, 2026 pursuant to the automatic increase feature of such plan, which provides that the number of shares reserved for issuance under the 2019 Plan will automatically increase on January 1st of each year, for a period of not more than ten years, commencing on January 1, 2020 and ending on (and including) January 1, 2029, in an amount equal to the lesser of (i) 5% of the total number of shares of the Registrants capital stock outstanding on December 31st of the preceding calendar year and (ii) a number of shares of Common Stock designated by action of the Registrants board of directors prior to the applicable January 1st.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <sup>2</sup> Pursuant to Rule 416(a) under the Securities Act, this Registration Statement shall also cover any additional shares of Common Stock of the Registrant that become issuable under the Registrants 2019 Employee Stock Purchase Plan (the 2019 ESPP) by reason of any stock dividend, stock split, recapitalization or other similar transaction. Estimated solely for the purpose of calculating the amount of the registration fee pursuant to Rules 457(c) and 457(h) of the Securities Act. The proposed maximum aggregate offering price per unit and proposed maximum aggregate offering price are calculated using the average of the high and low prices of the Common Stock as reported on the Nasdaq Global Market on February 20, 2026, which date is within five business days prior to the filing of this Registration Statement, multiplied by 85%. The number of shares being registered represents shares of Common Stock that were automatically added to the shares available for issuance under the 2019 ESPP on January 1, 2026 pursuant to the automatic increase feature of such plan, which provides that the number of shares reserved for issuance under the 2019 ESPP will automatically increase on January 1st of each year, for a period of not more than ten years, commencing on January 1, 2020 and ending on (and including) January 1, 2029, in an amount equal to the lesser of (i) 1% of the total number of shares of the Registrants capital stock outstanding on December 31st of the preceding calendar year, (ii) 1,500,000 shares of Common Stock and (iii) a number of shares of Common Stock designated by action of the Registrants board of directors prior to the applicable January 1st.

---

| | |
|:---|:---|
| | |
| **Rule 457(p)** | **Rule 457(p)** |
| Fee Offset Claims | N/A |
| Fee Offset Sources | N/A |

---

## Exhibit 5.1

**Exhibit 5.1**<br>

![image_0.jpg](image_0.jpg)

Jason L. KentT: +1 858 550 6044jkent@cooley.com <br>

February 25, 2026

Mirum Pharmaceuticals, Inc.

989 East Hillsdale Boulevard, Suite 300

Foster City, California 94404

Ladies and Gentlemen:

We have acted as counsel to Mirum Pharmaceuticals, Inc., a Delaware corporation (the "***Company***"), in connection with the filing by the Company of a registration statement on Form S-8 (the "***Registration Statement***") with the Securities and Exchange Commission (the "***Commission***"), covering the offering of up to 3,113,782 shares (the "***Shares***") of the Company's common stock, par value $0.0001 per share (the "***Common Stock***"), consisting of (i) 2,594,819 shares of Common Stock issuable pursuant to the Company's 2019 Equity Incentive Plan (the "***2019 Plan***"), and (ii) 518,963 shares of Common Stock issuable pursuant to the Company's 2019 Employee Stock Purchase Plan (together with the 2019 Plan, the "***Plans***").

In connection with this opinion, we have examined and relied upon (i) the Registration Statement and related prospectuses, (ii) the Plans, (iii) the Company's certificate of incorporation and bylaws, each as currently in effect, and (iv) such other records, documents, opinions, certificates, memoranda and instruments as in our judgment are necessary or appropriate to enable us to render the opinion expressed below. We have assumed the genuineness of all signatures, the authenticity of all documents submitted to us as originals, the conformity to originals of all documents submitted to us as copies, the accuracy, completeness and authenticity of certificates of public officials, and the due authorization, execution and delivery of all documents by all persons other than the Company. As to certain factual matters, we have relied upon a certificate of an officer of the Company and have not independently verified such matters.

Our opinion is expressed only with respect to the General Corporation Law of the State of Delaware. We express no opinion to the extent that any other laws are applicable to the subject matter hereof and express no opinion and provide no assurance as to compliance with any federal or state securities law, rule or regulation.

On the basis of the foregoing, and in reliance thereon, we are of the opinion that the Shares, when sold and issued in accordance with the Plans, the Registration Statement and the related prospectuses, will be validly issued, fully paid and nonassessable (except as to Shares issued pursuant to deferred payment arrangements, which will be fully paid and nonassessable when such deferred payments are made in full).

This opinion is limited to the matters expressly set forth in this letter, and no opinion has been or should be implied, or may be inferred, beyond the matters expressly stated. This opinion speaks only as to law and facts in effect or existing as of the date hereof, and we have no obligation or responsibility to update or supplement this opinion to reflect any facts or circumstances that may hereafter come to our attention or any changes in law that may hereafter occur.

Cooley LLP 55 Hudson Yards, New York, NY 10001-2157<br>t: (212) 479 6000 f: (212) 479 6275 cooley.com

------

![image_0.jpg](image_0.jpg)

February 25, 2026Page Two <br>

We consent to the filing of this opinion as an exhibit to the Registration Statement. In giving such consent, we do not thereby admit that we are in the category of persons whose consent is required under Section 7 of the Securities Act of 1933, as amended, or the rules and regulations of the Commission thereunder.

Sincerely,

Cooley LLP

By: <u>/s/ Jason L. Kent&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</u>

Jason L. Kent

Cooley LLP 55 Hudson Yards, New York, NY 10001-2157<br>t: (212) 479 6000 f: (212) 479 6275 cooley.com

## Exhibit 23.1

Exhibit 23.1

**Consent of Independent Registered Public Accounting Firm**

We consent to the incorporation by reference in the Registration Statement (Form S-8) pertaining to the 2019 Equity Incentive Plan and the 2019 Employee Stock Purchase Plan of Mirum Pharmaceuticals, Inc. of our reports dated February 25, 2026, with respect to the consolidated financial statements of Mirum Pharmaceuticals, Inc. and the effectiveness of internal control over financial reporting of Mirum Pharmaceuticals, Inc. included in its Annual Report (Form 10-K) for the year ended December 31, 2025, filed with the Securities and Exchange Commission.

/s/ Ernst & Young LLP

San Mateo, California

February 25, 2026

<br>